Ian Michael Estepan sold $294k of SRPT
Chief Operating Officer at Sarepta Therapeutics, Inc.. 13,187 shares at an average of $22.31, traded Dec 16, 2025, filed Dec 18, 2025.
Score components
- +20RoleCOO
- +14Trade size$294k at market
- 0Share of holdings soldSold 6.4% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +3.9%, 3m -18.1%, 6m -13.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-325383, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 16, 2025 | SOpen-market sale Common Stock | -13,187 | $22.31 | $294k | 193,300 | Dec 18, 2025 |
Related signals
Other insiders at Sarepta Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | SRPTsell Sarepta Therapeutics, Inc. | Stephen Mayo director | $123k 7,239 shares | -80% | |
| 43Moderate | Sarepta Therapeutics, Inc. | Hans Lennart Rudolf Wigzell director | $1.3M 10,500 shares | -31% | |
| 40Moderate | Sarepta Therapeutics, Inc. | Kathryn Jean Boor director | $205k 1,636 shares | -22% | |
| 23Weak | Sarepta Therapeutics, Inc. | Bilal Arif Chief Tech Ops Officer | $1.9M 11,757 shares | -40% | |
| 33Weak | Sarepta Therapeutics, Inc. | Ryan Edward Brown EVP, General Counsel | $6.3M 38,957 shares | -69% | |
| 40Moderate | Sarepta Therapeutics, Inc. | Kathryn Jean Boor director | $94k 761 shares | -9% | |
| 50Moderate | Sarepta Therapeutics, Inc. | Hans Lennart Rudolf Wigzell director | $1.8M 15,000 shares | -40% | |
| 56Moderate | Sarepta Therapeutics, Inc. | Stephen Mayo director | $385k 3,135 shares | -32% | |
| 43Moderate | Sarepta Therapeutics, Inc. | Bilal Arif Chief Tech Ops Officer | $258k 2,000 shares | -7% | |
| 43Moderate | Sarepta Therapeutics, Inc. | Ryan Edward Brown EVP, General Counsel | $251k 2,000 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.